Business Wire

Cyara Accelerates Growth With Senior Global Appointments

16.11.2022 00:00:00 EET | Business Wire | Press release

Share

Cyara, provider of the leading Automated Customer Experience (CX) Assurance Platform, has appointed Max Lipovetsky to the role of VP Products and Russ Hellmann to VP Growth Marketing, as it accelerates its global foothold.

With over 20 years’ experience in the contact centre and IVR industry, Max Lipovetsky brings a wealth of knowledge as Cyara’s VP Products. In 2003, Max co-founded Global Speech Networks and brought to market one of the first SaaS contact centre clouds - capturing the attention of some of ANZ’s largest businesses. Based in Melbourne, Australia, Max will be instrumental in guiding Cyara through its next stage of product innovation, including the fast-evolving role of AI in testing.

Russ Hellmann, Fujitsu’s former Head of Global Demand - Digital Innovation, joins Cyara in the newly created role of VP Growth Marketing. Based in Texas, US, he will be responsible for developing a centralised capability for regional teams that will enable customer acquisition and partner activation. Russ will lead four strategic pillars of growth - Global Programmes, Digital Marketing, Field Marketing and Partner Marketing - which, together, will play an influential role in planning, building and activating campaigns that will enable Cyara to scale at speed.

These two significant additions to Cyara’s senior team follow last month’s appointments of Dean Saunders, Channel and Alliances Director of APAC, and Vikram Verma, Cyara’s first independent board member.

Max Lipovetsky, VP Products, said, “Cyara brings agility and accelerated innovation to CX, turbo-charging businesses that are driven to create the best possible experiences for their customers. Cyara does this through CX Assurance; a product category it has created almost single-handedly on a global scale. With its history of innovation and an organisational platform built for growth I’m incredibly excited to be joining Alok and the team.”

Russ Hellmann, VP Growth Marketing, said, “CX is both an art and a science - and only Cyara can measure, test and optimize for both. As the rapid and fundamental shift to the cloud continues, ensuring every facet of the CX journey is seamless has become paramount for success. With Cyara’s comprehensive assurance capabilities, expansive global partnerships and passionate people, I’m thrilled to be joining a fast-growing category leader that is pushing and redefining boundaries.”

Alok Kulkarni, CEO and Co-Founder of Cyara, added, “Securing talent like Max and Russ to help drive our product innovation, value proposition and growth strategy, places Cyara in a very unique, and fortunate position as we head into 2023. We are entering a period of massive disruption within our industry which will create risks and opportunities along the way. From our growth ambitions to our employee happiness, ensuring we have the right leaders in place is vital and I can’t wait to see the impact both Russ and Max will create for customers, partners and the team.”

About Cyara

Cyara is the world’s leading Automated Customer Experience (CX) Assurance platform, headquartered in Silicon Valley. Cyara’s cloud-based omnichannel assurance solutions for voice quality and chatbot testing accelerate the delivery of flawless customer journeys for enterprises while reducing the risk of customer-facing defects. Every day, major global brands trust the Cyara Platform to deliver customer smiles at scale. For more information, please visit cyara.com.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Diana Gallagher
(408) 656-9699
10Fold Communications for Cyara
cyara@10fold.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Takeda Receives U.S. FDA Approval of MIMRYLO™ (rusfertide), Marking a Potential Shift in the Treatment Paradigm for Polycythemia Vera29.8.2026 01:40:00 EEST | Press release

Takeda (TSE:4502/NYSE:TAK)announced U.S. Food and Drug Administration (FDA) approval of the New Drug Application (NDA)* for MIMRYLO™ (rusfertide) for the treatment of erythrocytosis in adults with polycythemia vera (PV), a blood cancer. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260824773270/en/ MIMRYLO Logo MIMRYLO is a first-in-class hepcidin mimetic designed to regulate iron distribution in the body and red blood cell overproduction to control hematocrit levels, which is the ratio of red blood cells to the total amount of blood in the body. Maintaining controlled hematocrit levels below 45% is the primary treatment goal in PV.1 “For patients living with PV, uncontrolled hematocrit can have serious consequences, including an elevated risk of life-threatening thrombotic events," said Andrew T. Kuykendall, M.D., VERIFY lead investigator and Associate Member in the Department of Hematology at Moffitt Cancer Center. “Curre

Rigaku and Tohoku University Establish a New Research Institute for X-Ray Metrology28.8.2026 17:00:00 EEST | Press release

Rigaku Corporation, a group company of Rigaku Holdings and a global solutions partner for X-ray analytical systems (Head Office: Akishima, Tokyo; President and CEO: Jun Kawakami; “Rigaku”), and Tohoku University (Sendai, Miyagi; President: Teiji Tominaga; “Tohoku University”) have established the Rigaku-Tohoku University Co-Creation Research Institute for X-ray Metrology: Beyond The Limits (the “Institute”) at Tohoku University on August 1, 2026. The Institute will advance X-ray metrology technology, develop new metrology methods, and foster the next generation of researchers through an initial three-year collaboration, with the possibility of extension based on its achievements. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260828688510/en/ Inside the Institute As semiconductors become smaller, more multilayered, and incorporate a wider range of materials, manufacturing processes are becoming increasingly complex. X-ray me

BLK: Portfolio Company of Enry’s Island S.p.A., Lists on Euronext Dublin28.8.2026 16:34:00 EEST | Press release

Enry’s Island S.p.A. (WBAG:EIOS), an international venture builder with headquarters in the Tremiti Islands and the Metaverse, announces that BLK Global PLC, one of the portfolio companies within its ecosystem, has successfully completed its admission to trading on Euronext Access Dublin. Trading in the company’s shares commenced on Friday, July 31, 2026, under ticker BLKX and ISIN GB00BPSKS130. BLK was one of the thousands of applications received by Enry’s Island which, following an assessment process based on the Enry’s Model, was selected for a one-year incubation and acceleration programme. The programme supported the company through its subsequent growth stages, ultimately leading to its current stock market listing. Alessandro Pacciana, Investor Relations Manager of Enry’s Island S.p.A., said: “BLK’s listing is the second stock market listing in two years among Enry’s Island’s portfolio companies, while Enry’s Island itself is the world’s first listed venture builder. We are pro

Zambon Announces European Commission Approval of Hopledo® for Adults with Parkinson's Disease and Moderate to Severe Motor Fluctuations28.8.2026 12:00:00 EEST | Press release

Zambon today announced that the European Commission (EC) has granted marketing authorization for Hopledo® (modified-release levodopa/carbidopa) for the treatment of adult patients with Parkinson’s disease and moderate to severe motor fluctuations who have not been sufficiently stabilized with oral levodopa/dopa decarboxylase (DDC) inhibitor-based treatment regimens. Zambon expects to begin the phased introduction of Hopledo® across European markets starting October 2026. The company is working closely with healthcare authorities and other stakeholders to support timely access for people with Parkinson’s disease who continue to experience moderate to severe motor fluctuations despite current oral therapies. Hopledo® is a first-in-class, oral, modified-release formulation of levodopa/carbidopa (LD/CD) approved for the treatment of motor fluctuations of Parkinson’s disease, the fastest growing neurological condition in the world according to the World Health Organization1. Despite availab

MTG-I2 Safely in Orbit, Unlocking Faster and Sharper Weather Monitoring Across Europe28.8.2026 11:16:00 EEST | Press release

The Meteosat Third Generation Imager 2 satellite (MTG-I2) has successfully passed its first critical post-launch milestones, completing the first full Meteosat Third Generation constellation in orbit. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260828243790/en/ Credit: Arianespace livestream The imager satellite MTG-I2 is safely in orbit and operating as expected following its successful launch yesterday at 22:11 CEST on board an Ariane 6 rocket from Europe’s Spaceport in French Guiana. Our teams have established communication with the spacecraft, which has also deployed its solar panels to ensure its autonomous production of energy. MTG-I2 is in perfect shape to start its Launch and Early Operations Phase that will bring it to a higher orbit, 36 000km above Earth over the following two weeks, where a longer period of calibration and validation of its instruments will begin. This summer’s extreme weather and wildfires hav

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye